BPMX - BioPharmX Corporation

NYSE American - NYSE American Delayed Price. Currency in USD

BioPharmX Corporation

115 Nicholson Lane
San Jose, CA 95134
United States

Sector : Healthcare
Industry : Biotechnology
Full Time Employees : 17

Key Executives

Name Title Pay Exercised Year Born
Dr. David S. Tierney M.D. Pres, CEO, CFO & Director 440.27k N/A 1964
Mr. Steven M. Bosacki Chief Operating Officer N/A N/A N/A
Ms. Joyce Goto VP, Chief Accounting Officer & Controller N/A N/A 1974
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


BioPharmX Corporation, a specialty pharmaceutical company, develops products for the treatment of dermatologic conditions using its proprietary HyantX topical delivery system. Its clinical-stage product candidates include BPX01, a topical antibiotic gel that has completed Phase IIb clinical trial for the treatment of inflammatory lesions of acne; and BPX04, a topical antibiotic, which is in Phase IIb study for the treatment of inflammatory lesions of rosacea. The company serves pharmaceutical companies, physician's practices, dermatologists, and general practitioners. BioPharmX Corporation is headquartered in San Jose, California.

Corporate Governance

BioPharmX Corporation’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS) . Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.